FFO
CYTK icon

Fortitude Family Office’s Cytokinetics CYTK Stock Holding History

Fortitude Family Office’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.49K Buy
41
+23
+128% +$1.65K ﹤0.01% 1248
2026
Q1 		$1.19K Buy
18
+13
+260% +$826 ﹤0.01% 1460
2025
Q4 		$318 Sell
5
-2
-29% -$124 ﹤0.01% 1813
2025
Q3 		$385 Hold
7
– – ﹤0.01% 1866
2025
Q2 		$231 Sell
7
-8
-53% -$278 ﹤0.01% 1947
2025
Q1 		$603 Hold
15
– – ﹤0.01% 1074
2024
Q4 		$706 Hold
15
– – ﹤0.01% 1184
2024
Q3 		$792 Hold
15
– – ﹤0.01% 1121
2024
Q2 		$813 Hold
15
– – ﹤0.01% 896
2024
Q1 		$1.05K Hold
15
– – ﹤0.01% 903
2023
Q4 		$1.25K Buy
+15
New +$543 ﹤0.01% 924

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fortitude Family Office's CYTK Position: Q2 2026 in Review

Fortitude Family Office increased its Cytokinetics (CYTK) stake by 128% in Q2 2026, buying an estimated $1.65K and bringing the position to 41 shares worth $3.49K. The position accounts for ﹤0.01% of the portfolio, ranked #1248.

Fortitude Family Office first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Fortitude Family Office held 41 shares of Cytokinetics worth $3.49K as of Q2 2026.
  • Fortitude Family Office bought 23 Cytokinetics shares in Q2 2026, an estimated $1.65K.
  • Cytokinetics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1248 holding.
  • Fortitude Family Office first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.